Central Nervous System News and Research

RSS

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

22 Jan 2014

Study provides new information about life expectancy of people with multiple sclerosis

The first large scale study in the U.S. on the mortality of patients with multiple sclerosis has been published and provides new information about the life expectancy of people with the disease. The study appears in the journal Multiple Sclerosis and Related Disorders.

21 Jan 2014

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, announced that reported diluted earnings per share equaled $0.07 in the third quarter of fiscal 2014, compared to a reported loss per share of ($0.58) in the third quarter of fiscal 2013. The third quarter of fiscal 2014 included a $45 million charge ($28.2 million net of tax) related to Project Rejuvenate.

21 Jan 2014

Patients with MS could stave off disease symptoms by increasing vitamin D intake

For patients in the early stages of multiple sclerosis (MS), low levels of vitamin D were found to strongly predict disease severity and hasten its progression, according to a new study led by Harvard School of Public Health (HSPH) investigators in collaboration with Bayer HealthCare.

20 Jan 2014

Robot-assisted therapy shows increased mobility after paresis

The survivors of a stroke often struggle with persistent loss of function of the central nervous system. Around the world strokes are one of the most frequent causes of paresis.

17 Jan 2014

Severe infection associated with increased risk for psychotic illness

Hospital admission for infections in childhood is associated with an increased risk for being diagnosed with nonaffective psychosis later in life, research indicates.

16 Jan 2014

Study reveals high prevalence of TB infection among young children

A small study by investigators from the Johns Hopkins Children's Center and Byramjee Jeejeebhoy Government Medical College in India reveals high prevalence of tuberculosis infection among young children, troubling rates of disseminated disease and alarming patterns of drug resistance.

15 Jan 2014

Individuals with multiple sclerosis may have increased risk of developing cancer

Individuals with multiple sclerosis may have an increased risk of developing any type of cancer, with an especially high risk of developing breast cancer. That is the conclusion of a recent study published in European Journal of Neurology. Because the findings contradict earlier studies, additional research is needed to determine whether a true link exists between multiple sclerosis and cancer.

15 Jan 2014

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models.

10 Jan 2014

Norwegian researchers map genetic variations associated with increased risk of MS and MG

The Norwegian researchers have taken part in an international cooperative effort to map 110 genetic variations that increase the risk of MS and MG. Most of these genetic variations have been mapped in recent years.

9 Jan 2014

IQWiG study finds no added benefit of teriflunomide

Teriflunomide (trade name: Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

8 Jan 2014

Synthetic cannabinoid molecule created for osteoarthritis

Chemical compounds synthesised in the laboratory, similar to those found in cannabis, could be developed as potential drugs to reduce the pain of osteoarthritis.

7 Jan 2014

Ossianix forms strategic research partnership with Lundbeck

Ossianix, Inc. today announced a strategic research collaboration with Lundbeck A/S. This collaboration follows a previous investment in 2012. The collaboration uses Ossianix's innovative single domain antibody platform based on the shark VNAR structure and will focus on two projects.

6 Jan 2014

Portage acquires approximately 54% equity in Biohaven

Portage Biotech Inc., is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited, a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months.

6 Jan 2014

Kindergarten teacher diagnosed with rare neurological syndrome

The journal Neurology is reporting an unusual and heart-rending case of a reading teacher who suddenly lost her ability to read.

6 Jan 2014

Novel technique helps people with word blindness to read again

In the journal Neurology, researchers report a novel technique that enables a patient with "word blindness" to read again.

3 Jan 2014

MitoQ antioxidant reverses MS-like disease in animal

Researchers at Oregon Health & Science University have discovered that an antioxidant designed more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease.

27 Dec 2013

Research: Neuropeptides may serve as index for evaluating early peripheral nerve injury

Substance P and calcitonin gene-related peptide are the main neuropeptides in peripheral nerve ganglia, which can anterogradely transmit nociceptive information to the central nervous system.

27 Dec 2013

Stakeholders agree that regulators not adequately prepared to manage risks posed by nanotechnology

Three stakeholder groups agree that regulators are not adequately prepared to manage the risks posed by nanotechnology, according to a paper published in the peer-reviewed journal PLOS One. In a survey of nano-scientists and engineers, nano-environmental health and safety scientists, and regulators, researchers at the UCSB Center for Nanotechnology in Society (CNS) and at the University of British Columbia found that those who perceive the risks posed by nanotechnology as "novel" are more likely to believe that regulators are unprepared.

23 Dec 2013

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Physicians at the Ruhr-Universität Bochum (RUB) have been investigating if established anti-epilepsy drugs have anti-inflammatory or pro-inflammatory properties - an effect for which these pharmaceutical agents are not usually tested.

20 Dec 2013

Central Nervous System News and Research

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

Study provides new information about life expectancy of people with multiple sclerosis

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Patients with MS could stave off disease symptoms by increasing vitamin D intake

Robot-assisted therapy shows increased mobility after paresis

Severe infection associated with increased risk for psychotic illness

Study reveals high prevalence of TB infection among young children

Individuals with multiple sclerosis may have increased risk of developing cancer

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

Norwegian researchers map genetic variations associated with increased risk of MS and MG

IQWiG study finds no added benefit of teriflunomide

Synthetic cannabinoid molecule created for osteoarthritis

Ossianix forms strategic research partnership with Lundbeck

Portage acquires approximately 54% equity in Biohaven

Kindergarten teacher diagnosed with rare neurological syndrome

Novel technique helps people with word blindness to read again

MitoQ antioxidant reverses MS-like disease in animal

Research: Neuropeptides may serve as index for evaluating early peripheral nerve injury

Stakeholders agree that regulators not adequately prepared to manage risks posed by nanotechnology

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Event guide: The 7th CNS Drug Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News